Tryptyr, acoltremon ophthalmic solution

About Tryptyr

Tryptyr (acoltremon ophthalmic solution) is manufactured by Alcon and was approved by the US FDA in 2025 for the signs and symptoms of dry eye disease. It is administered as a topical eye drop, not a systemic agent.

The molecule is a selective TRPM8 receptor agonist. TRPM8 is a cold-thermoreceptor expressed on corneal sensory afferents; activating it stimulates basal tear production through the natural reflex arc rather than supplementing the tear film artificially. Tryptyr is the first FDA-approved TRPM8 agonist for dry eye disease.

Tryptyr may be accessible to international patients through Named Patient Program or personal-import pathways where the molecule is not yet locally registered.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Tryptyr

1. Patient or treating physician submits a named-patient request.
2. Clinical team verifies appropriateness of Tryptyr for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific NPP / personal-import documentation is prepared.
5. Tryptyr is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Access by country

Reserve Meds publishes a detailed country deep-dive for Tryptyr in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Start a request for Tryptyr

Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.

Start your case Or message us on WhatsApp